• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Bausch Health gets Canadian rights to Glenmark’s Ryaltris nasal spray

Bausch Health has acquired the rights to commercialize Glenmark’s Ryaltris olopatadine / mometasone furoate nasal spray in Canada, Glenmark has announced. According to Glenmark, which is responsible for regulatory approval under the agreement with Bausch, Health Canada is currently reviewing the company’s marketing application for Ryaltris for the treatment of seasonal allergic rhinitis.

Hikma Pharmaceuticals acquired US rights Ryaltris in February 2020, and Menarini aquired European rights to Ryaltris in December 2020. The FDA issued a complete response letter to Glenmark’s NDA for Ryaltris in June 2019; the company says that the NDA is currently under review.  

Glenmark Pharmaceuticals President & Business Head, North America, Sanjeev Krishan commented, “We are pleased to partner with Bausch Health Canada, and recognize their strong foothold in the prescription and OTC market in Canada. This agreement will help us reach a larger patient population and extend the multiple benefits of Ryaltris to a significant market. Glenmark continues to build a strong portfolio in respiratory medicine, and Ryaltris marks our first true global brand launch till date.”  

Bausch Health, Canada President Richard Lajoie said, “We are pleased to add Ryaltris to our allergy product portfolio and eager to make it available to Canadian patients suffering from allergies.”

Read the Glenmark Pharmaceuticals press release.

Share

published on March 23, 2021

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews